Asim Siddiqui

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.

Life Technologies, Inc. provides essential technologies needed by the biotechnology and biopharmaceutical communities. The company manufactures and markets a breadth of offerings unique in the industry, used in applications of the life sciences discovery, development, and production process

BC Cancer Agency Genome Sciences Centre provides cancer therapy services. The company is headquartered in Vancouver, Canada.

Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada.